INMED PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
INMED PHARMACEUTICALS INC. (INM) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of -$106.87 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was -$191.11K.
- INMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $38.77K, a 4.16% decline year-over-year.
- INMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $25.26K, a 9.09% increase year-over-year.
- INMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $20.20K, a 30.24% decline year-over-year.
- INMED PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $278.15K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$191.11K derived: S-4/A 12 month − 3 quarters · filed 2026-09-09 | -$152.34K derived: sum of 2 quarters · filed 2026-09-09 | -$127.07K derived: sum of 3 quarters · filed 2026-09-09 | -$106.87K S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | $38.77K S-4 · filed 2026-07-02 | -$38.77K 10-Q · filed 2026-05-06 | $64.03K derived: sum of 2 quarters · filed 2026-07-02 | $84.24K derived: sum of 3 quarters · filed 2026-07-02 | ||
| 2025-12-31 | $25.26K S-4 · filed 2026-07-02 | -$25.26K 10-Q · filed 2026-02-11 | $45.47K derived: sum of 2 quarters · filed 2026-07-02 | |||
| 2025-09-30 | $20.20K S-4 · filed 2026-07-02 | -$20.20K 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | -$119.31K S-4/A · filed 2026-09-09 | $119.31K 10-K · filed 2025-09-23 | ||||
| 2025-03-31 | $40.45K S-4 · filed 2026-07-02 | $63.61K derived: sum of 2 quarters · filed 2026-07-02 | $92.58K derived: sum of 3 quarters · filed 2026-07-02 | |||
| 2024-12-31 | $23.16K S-4 · filed 2026-07-02 | $52.12K derived: sum of 2 quarters · filed 2026-07-02 | ||||
| 2024-09-30 | $28.96K S-4 · filed 2026-07-02 | |||||
| 2024-06-30 | $137.72K S-4 · filed 2026-07-02 | $137.71K 10-K · filed 2024-09-30 | ||||
| 2024-03-31 | $55.30K 10-Q · filed 2025-05-12 | $73.57K derived: sum of 2 quarters · filed 2025-05-12 | $98.76K derived: sum of 3 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $18.26K 10-Q · filed 2025-05-12 | $43.45K derived: sum of 2 quarters · filed 2025-05-12 | ||||
| 2023-09-30 | $25.19K 10-Q · filed 2025-05-12 | |||||
| 2023-06-30 | $278.15K 10-K · filed 2024-09-30 | |||||
| 2022-12-31 | $70.64K 10-Q · filed 2024-02-13 | $187.32K derived: sum of 2 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | $116.68K 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |